Journal of Antimicrobial Chemotherapy, Vol 39, 647-649, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
PM Roblin, A Kutlin, N Sokolovskaya and MR Hammerschlag
The in-vitro susceptibilities of 12 strains of Chlamydia pneumoniae were
determined for dirithromycin, a new macrolide antibiotic,
erythromycyclamine, its active metabolite, and erythromycin. Both
dirithromycin and erythromycyclamine had an MIC90 of 2 mg/L, as compared
with 0.062 mg/L for erythromycin. The combination of dirithromycin and
erythromycyclamine appeared to be additive. Determination of the role of
dirithromycin for the treatment of C. pneumoniae infection will depend on
the results of prospective, controlled studies utilizing culture.
JOURNAL ARTICLE
In-vitro activity of dirithromycin against Chlamydia pneumoniae
Department of Pediatrics, State University of New York, Health Science Center at Brooklyn, 11203, USA.
![]()
CiteULike
Connotea
Del.icio.us What's this?